ALFA Finder| Revenue growth | 96.4% YoY Consolidated |
|---|---|
| Margins | Grain-based operations 6% more profitable than sugar-based |
| Demand visibility | Strong visibility from ethanol blending beyond E20 |
| Management confidence | High |
Growth
Consolidated Total Income grew 96.37% YoY; EBITDA increased 219.62% to ₹132.76 Cr; PAT surged 1154.37% to ₹59.27 Cr.
Outlook
Targeting 24-30 months for SAF facility commissioning; 4 CBG plants commissioned by Q4 FY27; Phase 1 retail network 100-outlet rollout.
Risks
Geopolitical instability, volatile crude oil prices, and regulatory shifts in ethanol blending and procurement environments.
Last quarter's promises, checked
Delivered
- Targeting dual-feed operations in 3/5 plants → Delivered (Completed conversion)
- Guided 7 retail fuel outlets → Delivered 7 outlets (₹100Cr+ revenue)
- Targeted 85%+ CBG capacity utilization → Delivered 85%+
Partly delivered
- Targeted 10 CBG plants by FY27 → 4 plants commissioned/underway (= PARTIAL)
Missed
- Guided 37 crore litres volume target → Delivered 24 crore litres (= MISS)
- Guided 15 crore litres court-ordered lifting → Delivered 0 litres (= MISS)
- Guided ₹350-400Cr monthly revenue run rate → Delivered ₹198Cr/mo (= MISS)
Investor Presentation filed with BSE, NSE: TRUALT. Summary written with AI assistance from the document.
TruAlt Bioenergy Ltd: key numbers
- Share price
- ₹350.00
- Market cap
- ₹3,001 Cr
- Revenue (annual)
- ₹1,728 Cr
- Net profit (annual)
- ₹95.95 Cr
- P/E (TTM)
- 13.6×Sector 29.0×
- Promoter holding
- 71.38%+0.83% QoQ
- FII holding
- 0.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TruAlt Bioenergy Ltd
All →TruAlt Bioenergy Other Announcement
TruAlt Bioenergy filed Crisil's monitoring agency report for the quarter ended 30 September 2026 on its Rs 750 crore IPO proceeds. The report notes no deviation from the IPO objects.
TruAlt Bioenergy Earnings Call Transcript: Key Takeaways
TruAlt reported massive 606% YoY revenue growth, turning profitable despite raw material price surges. Management is pivoting from ethanol to high-margin CBG to insulate from feedstock volatility.
TruAlt Bioenergy Investor Presentation: Key Takeaways
Q2 FY27 consolidated total income ₹823.74 Cr, PAT ₹34.99 Cr, EBITDA margin 12.47%. H1 PAT ₹94.27 Cr, EBITDA ₹233.92 Cr (16.27% margin). Strategy: integrated bioenergy across ethanol, CBG, SAF, retail.
TruAlt Bioenergy Results Update
TruAlt Bioenergy reported H1 FY27 revenue of ₹1,437.98 crore, EBITDA of ₹233.92 crore and PAT of ₹94.27 crore via press release. Results reverse last year's H1 loss.
TruAlt Bioenergy Q2 FY27 Results: Turns Profitable, Net Profit ₹35 Cr
TruAlt Bioenergy Ltd reported revenue from operations of ₹811.1 Cr (+605.9% YoY) and net profit of ₹35 Cr for Q2 FY27.
- Key figure
- Net profit ₹35 Cr
TruAlt Bioenergy Management Change
Mr. Monu Kumar resigned as Company Secretary and Compliance Officer of TruAlt Bioenergy Limited, effective October 16, 2026, due to personal reasons.